Fintel reports that on February 6, 2025, William Blair initiated coverage of Mersana Therapeutics (NasdaqGS:MRSN) with a ...

In a report released today, Tara Bancroft from TD Cowen maintained a Buy rating on Mersana Therapeutics (MRSN – Research Report). The company’s ...

In recent transactions disclosed by Mersana Therapeutics, Inc. (NASDAQ:MRSN), Timothy B. Lowinger, the company's Senior Vice President and Chief Science & Technology Officer, sold shares of common ...

The RSU award will vest in equal annual installments on the first four anniversaries of February 15, 2025, subject to the employee’s continued service with Mersana on each such vesting date. The RSU ...

CAMBRIDGE, Mass., Jan. 30, 2025 (GLOBE NEWSWIRE) -- (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) ...

Wedbush reiterated their outperform rating on shares of Mersana Therapeutics (NASDAQ:MRSN – Free Report) in a research report released on Friday morning,RTT News reports. They currently have a $ ...

Mersana Therapeutics has reported encouraging preliminary data from the Phase 1 trial of its lead antibody-drug conjugate, emiltatug ledadotin (Emi-Le), which targets B7-H4 in patients with ...

Mersana Therapeutics had a negative net margin of 214.20% and a negative return on equity of 401.37%. The company had revenue of $12.60 million for the quarter, compared to the consensus estimate ...

Mersana Therapeutics, Inc. CAMBRIDGE, Mass., Feb. 07, 2025 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and ...